Journal
LIVER INTERNATIONAL
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1111/liv.15668
Keywords
alcohol-related liver disease; cholangiocarcinoma; hepatitis C virus infection; hepatocellular carcinoma; nonalcoholic fatty liver disease
Categories
Ask authors/readers for more resources
We examined the changes in liver cancer-related mortality during the COVID-19 pandemic. The age-standardized mortality from hepatocellular carcinoma (HCC) showed a steady decrease, while the mortality from nonalcoholic fatty liver disease and alcohol-related liver disease demonstrated a linear increase. The mortality from intrahepatic cholangiocarcinoma (ICC) also showed a linear increase. The decline in HCC-related mortality can be attributed to a decrease in mortality caused by viral hepatitis.
We studied the trends in liver cancer-related mortality before and during the COVID-19 pandemic. Quarterly age-standardized mortality and quarterly percentage change (QPC) for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) were estimated using the US national mortality database 2017-2021. Quarterly age-standardized mortality from HCC decreased steadily with an average QPC of -0.4% (95% confidence interval [CI]: -0.6% to -0.2%). A decrease in hepatitis C virus and hepatitis B virus-related HCC mortality of -2.2% (95% CI: -2.4% to -1.9%) and -1.1% (95% CI: -2.0% to -0.3%) was noted. In contrast, mortality for HCC from nonalcoholic fatty liver disease (3.0%, 95% CI: 2.0%-4.0%) and alcohol-related liver disease (1.3%, 95% CI: 0.8%-1.9%) demonstrated a linear increase. There was a linear increase in the quarterly age-standardized ICC-related mortality (0.8%, 95% CI: 0.5%-1.0%). While ICC-related mortality continued to increase, HCC-related mortality tended to decline mainly due to a decline in mortality due to viral hepatitis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available